AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
AMCP webinar that reviewed the current pre-approval support features within FormuarlyDecisions.com and insights from the active FormularyDecisions.com Payer community.